DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG
/ Key word(s): Study
30.11.2021 / 10:55
The issuer is solely responsible for the content of this announcement.
Berlin / Toronto, 30 November 2021. Eckert & Ziegler Group is pleased to announce their partnership today with the Canadian Molecular Imaging Probe Consortium (CanProbe), a leader in the advancement and commercialization of novel radiopharmaceuticals to better serve patients and with the University Health Network (UHN), Canada’s largest health research organization affiliated with the University of Toronto. The partnership involves clinical research to further advance PentixaPharm’s Ga-68 radiodiagnostic tracer PENTIXAFOR in its detection of different tumour entities and other diseases.
The collaboration includes robust clinical exploration of the tracer in various applications and is set to include lymphoma, gynecological malignancies and lung cancer, as well as inflammatory conditions, all with the intent to further investigate the diagnostic potential of PENTIXAFOR and is set to include clinical trials with up to 300 doses administered.
Developed by PentixaPharm, PENTIXAFOR is an innovative imaging agent targeting the chemokine-4 receptor (CXCR4) for the diagnosis of cancer patients with various haemato-oncological and solid tumour indications. The Ga-68-based PET radiodiagnostic is expected to significantly improve the treatment of patients suffering from these diseases.
Eckert & Ziegler (ISIN DE0005659700, TecDAX) and its subsidiary, PentixaPharm GmbH, are working with CanProbe and UHN to provide PENTIXAFOR to patients in Toronto. The intent is to provide further support toward the approval of PENTIXAFOR as a diagnostic agent for a portfolio of different indications. In the spring of 2021, Eckert & Ziegler already received permission from the European Medicines Agency (EMA) to launch directly into a Phase III clinical trial, enabling the company to save a number of time-consuming evaluation steps. Clinical trials are scheduled to begin next year and include about 500 patients worldwide.
“Given the great potential of PENTIXAFOR, a number of physicians worldwide have decided to test the radiodiagnostic on their own initiative. The data collected in this way will support our approval of PENTIXAFOR, commented Dr. Hakim Bouterfa, co-founder and CEO of PentixaPharm GmbH.
“The great interest in PENTIXAFOR from nuclear physicians, oncologists and haematologists confirms our strategy to push the clinical development of the Ga-68 based radiodiagnostic,” explains Dr. Andreas Eckert, founder and CEO of Eckert & Ziegler AG.
“We are pleased to be working with PENTIXAFOR, as it is an imaging agent that potentially provides much clearer diagnostic images than can be achieved with conventional methods. We are hopeful that this will enable more targeted therapy options for patients,” comments Dr. Bruno Paquin, President of CanProbe. “We are delighted to see this partnership emerging between PentixaPharm, CanProbe, and UHN”, adds Luke Brzozowski, Senior Director, Techna and Diagnostics Innovation, University Health Network. “We are looking forward to seeing the results of the investigator-initiated studies at UHN with the tracer produced by CanProbe.”
About Eckert & Ziegler
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||Eckert & Ziegler Strahlen- und Medizintechnik AG|
|Phone:||+49 30 941084-138|
|Fax:||+49 30 941084-112|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1252836|
|End of News||DGAP News Service|